Panobinostat Regimen Yields Benefit for R/R Myeloma After Frontline ASCT

Video

Evidence from a matched pair comparison with a concurrent control cohort suggests that panobinostat plus gemcitabine, busulfan, and melphalan improves progression-free survival in those with relapsed or refractory multiple myeloma, especially after first transplant.

Panobinostat (Farydak) in combination with gemcitabine (Gemzar), busulfan (Busulfex), and melphalan (Megace Alkeran) produced positive evidence of clinical activity in patients with relapsed or refractory multiple myeloma, especially after first autologous stem cell transplant (ASCT), according to Yago L. Nieto, MD, PhD.

In an interview with CancerNetwork®, Nieto, a professor in the Department of Stem Cell Transplantation and Division of Internal Medicine at the University of Texas MD Anderson Cancer Center, described the design of a matched pair comparison with a concurrent control cohort (NCT02506959) assessing the regimen and detailing efficacy.

In a population of 80 patients who received the regimen, the median progression-free survival was 45 months, 21 months, and 32 months after frontline ASCT-1, first salvage ASCT-1, and second ASCT, respectively; the median follow-up was 51 months.

Lead author, Nieto, presented these findings as part of an abstract at the 2023 Tandem Meeting.

Transcript:

It was not a randomized trial but it's good evidence because a matched pair concurrent control analysis is likely the second-best evidence we have next to randomized trials. This [was a] rationally designed regimen of panobinostat, gemcitabine, busulfan, and melphalan.

I say ‘rationally’ because it was designed based on our work in the lab where we saw that there was striking synergism between panobinostat, which is the best HDAC inhibitor we have, and gemcitabine, busulfan and melphalan, with a great increase of cytotoxicity, apoptosis, and markers of DNA damage on the myeloma cells.

We saw that there's improvement of progression-free survival, which is a perfectly valid end point given that overall survival requires much longer follow-up. It's also contingent on the therapies you have available upon relapse, [which] keep getting better. It's going to be very difficult to encounter overall survival differences in myeloma in any study.

We saw that there's an improvement of progression-free survival compared with our matched controls when first transplant is done, either for patients with high-risk disease or relapsed disease. In the future, it may be the only kind of transplant we're going to be doing for myeloma; second transplants may not play much of a role given the availability of CAR T and other therapies.

Reference

Nieto Y, Yang Z, Valdez BC, et al. Safety and efficacy of a new high-dose chemotherapy regimen of panobinostat, gemcitabine, busulfan and melphalan (Pano/GBM) with autologous stem cell transplant (ASCT) for patients with high-risk or refractory/relapsed myeloma – matched pair comparisons with a concurrent control cohort. Transplantation and Cellular Therapy. 2023;29(suppl 2):S31-S32.

Recent Videos
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
The 3 most likely directions of radiotherapy advancements come from new technology, combinations with immunotherapy, and the incorporation of particle therapy.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
4 experts in this video
4 experts in this video
Distance and training represent 2 major obstacles to making radiotherapy available to more patients with cancer across the world.
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
Louis Potters, MD, FASTRO, FABS, FACR, describes how evidence-based radiation protocols may integrate with novel artificial intelligence software.
Related Content